Entering text into the input field will update the search result below

Sunesis lowers revenues 55% in Q3

  • Sunesis Pharmaceuticals (SNSS) Q3 results: Revenues: $0.9M (-55.0%); R&D Expense: $6.9M (-1.4%); G&A: $7.2M (+157.1%); Operating Loss: ($13.3M) (-70.5%); Net Loss: ($15.3M) (-101.3%); Loss Per Share: ($0.25) (-56.3%); Quick Assets: $44.7M (+13.7%).
  • No guidance given.

Recommended For You

More Trending News

About VIRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VIRX--
Viracta Therapeutics, Inc.